Maastricht University

BARCELONA, Spain, Jan. 17, 2025 /PRNewswire/ -- Results from a study funded by the International Nut and Dried Fruit Council have been published in the journal Nutrients.[1] The study showed that longer-term consumption of mixed nuts may lower cardiovascular disease (CVD) risk in older adults with obesity or overweight, potentially aiding in the development of accessible dietary interventions to improve cardiovascular health in at-risk populations. The newly published study builds on earlier research that showed consuming mixed nuts over a long-term period significantly reduced total and LDL ('bad') cholesterol levels. It aimed to provide a more comprehensive understanding of the relationship between nut consumption and lipoprotein-related CVD risk. The study found that eating mixed nuts significantly improved blood lipid levels, creating a more heart-healthy profile, including changes in certain lipoprotein subclasses related to better heart health. The results provide deeper insights into how nuts can influence blood lipids. Dr. Peter Joris and Dr. Kevin Nijssen from Maastricht University, Netherlands, stated, "Based on these results, we have concluded that incorporating mixed nuts into the diet may contribute to reduce the risk of CVD in older adults." The study was a randomized, controlled crossover trial that analyzed the effects of the daily consumption of mixed nuts on lipoprotein particle levels in older adults with obesity or overweight. Twenty-eight participants completed two 16-week phases: a control period with no nut consumption and an intervention period where they consumed 60 grams/day of mixed nuts (15 g each of walnuts, pistachios, cashews, and hazelnuts). The two phases were separated by an 8-week washout period. The investigators evaluated the effect of nut consumption on lipoprotein particle numbers, sizes, and lipid content across various lipoprotein subclasses using an advanced NMR metabolomics platform. About the INC The INC is the global umbrella organization for the nut and dried fruit industry, representing over 900 companies across 85 countries and 85% of global trade. Its mission is to drive sustainable growth and serve as the leading authority on health, nutrition, statistics, food safety, and international standards for nuts and dried fruits. [1] Nijssen, K. M. R., Chavez-Alfaro, M. A., Joris, P. J., Plat, J., & Mensink, R. P. (2025). Effects of Longer-Term Mixed Nut Consumption on Lipoprotein Particle Concentrations in Older Adults with Overweight or Obesity. Nutrients, 17(1), 8. Logo: SOURCE International Nut & Dried Fruit Council (INC) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Alessandra Micaela Villa appointed Director of Platform Development Rob Roovers appointed Director of Preclinical Development AMSTERDAM, Dec. 10, 2024 /PRNewswire/ -- Kling Biotherapeutics ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announces the appointments of Alessandra Micaela Villa as Director of Platform Development and Rob Roovers as Director of Preclinical Development, as it strengthens its leadership team to progress its pipeline across cancer and infectious diseases. Alessandra joins from Molecular Partners, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPins. Rob was previously head of preclinical development at LAVA Therapeutics, a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma delta T cell engagers. Michael Koslowski, Chief Executive Officer at Kling Biotherapeutics, said: "Alessandra and Rob's appointments come at a pivotal time of growth and development for Kling. By utilizing our groundbreaking commercially validated primary B-cell selection and evolution platform to identify therapeutic antibodies from B-cells of 'exceptional responders', we are laser-focused on developing best-in-class therapeutics for cancer and infectious diseases." Prior to Molecular Partners, Alessandra led the Antibody Research and Phage Display Technology to design and develop anti-cancer immunocytokines from R&D into IND-enabling studies. Alessandra has a PhD in the Generation and Engineering of Therapeutic Antibodies for Tumour Targeting from ETH-Zürich and holds an MSc in Industrial Biotechnology from Università degli Studi di Milano-Bicocca. Before his time at LAVA Therapeutics, Rob worked at Merus, where he co-developed Merus' bispecifics, of which two are on the verge of being registered drugs. He has a PhD in Antibody Engineering and Development in Oncology from the University of Maastricht, after which he completed his postdoctoral studies at the Dutch Cancer Institute and Utrecht University. Rob holds an MSc in Cell/Cellular and Molecular Biology and Immunology from the Radboud University in Nijmegen. About Kling Biotherapeutics Kling Biotherapeutics is a privately held biotech company focused on the discovery and development of novel targets and therapeutics. The Company is headquartered in Amsterdam, the Netherlands with a fully owned IP portfolio that covers its proprietary platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel, fully human antibodies directly from patient-derived B cells and the targets they recognize. Kling-Select relies on a fully-owned and clinically validated B cell immortalization and screening technology to identify novel therapeutic antibody binders and targets from patients with exceptional clinical responses. This technology has successfully identified novel neutralizing antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective antibody-target pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to more traditional target discovery approaches. Kling-Evolve enables the ex vivo affinity maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of antibody assets in oncology. SOURCE Kling Biotherapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BERLIN, GERMANY / ACCESSWIRE / April 3, 2024 / Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment against Long COVID, appoints six distinguished scientists to a new advisory board. The aim of the board is to advise on industry developments and new growth potentials, as well as to support research and development that will further strengthen the portfolio of Berlin Cures and thus the successful market launch of new therapies. The new board includes the following scientists: Prof. Friedemann Paul , neuroimmunologist and Vice Dean at the Charité in Berlin; Prof. Stephane Heymans , Professor of Cardiomyopathy and Head of the Centre for Heart Failure Research at Maastricht University; Prof. Carl Erb , ophthalmologist in Berlin specializing in glaucoma and neuroprotective research; Prof. John McMurray , Professor of Medical Cardiology at the University of Glasgow, focusing on heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, recipient of the OBE and the ESC Gold Medal; Prof. Carmen Scheibenbogen , immunologist at the Charité Berlin, focusing on ME/CFS and Long COVID; and Prof. Christian Mardin , ophthalmologist at the University Hospital Erlangen, specializing in glaucoma research and biomarkers for Long COVID and autoimmune diseases. "We are very pleased to now work with six renowned scientists who have achieved great success in their respective fields of research. Their expertise will significantly accelerate our mission to develop groundbreaking therapies for various diseases. Berlin Cures has been known for innovative and effective research for years. With our platform technology, we aim to provide effective therapies for the treatment of diseases associated with functional autoantibodies, including Long COVID, heart failure, glaucoma, and ME/CFS," says Oliver von Stein, CEO of Berlin Cures . Berlin Cures, a biotechnology company specializing in the neutralization of functional autoantibodies (fAABs), is currently conducting a Phase II clinical trial for its drug BC 007 for Long COVID. The study, which began in June 2023, is being conducted in five countries and 12 study centers. Over 75% of the targeted 114 patients have already been enrolled in the study. The study results, expected in autumn 2024, will pave the way for the next phase of development: Berlin Cures is actively engaged in fundraising to capitalize on future opportunities to support a Phase III study necessary for regulatory approval and to advance the clinical development of other programs. Biographies of the new advisory board members can be found here . Recruiting study centers can be found here . About Berlin Cures: The Berlin Cures team has dedicated over two decades to the research of functional autoantibodies (fAABs) and has successfully identified a molecule capable of effectively neutralizing these. Promising preclinical results have been observed for BC 007. In a recently completed Phase IIa trial with patients with chronic heart failure, BC 007 demonstrated long-term autoantibody neutralization after a single dose resulting in significant improvement in cardiac function, with no spontaneous disappearance of autoantibodies in untreated patients. Its potential as an effective therapy for Long COVID was realized when tests on sera from Long COVID patients proved positive for fAABs, supported by clinical observations in four case studies. By addressing the underlying cause of fAAB-associated diseases with this unique biotechnology, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue at its core. Since June 2023, Berlin Cures has been absolving a Phase II clinical trial with BC 007 in the indication Long COVID, an acute and escalating global health problem, to obtain meaningful and robust results on efficacy and tolerability of BC 007 with patients suffering from Long COVID. Contact: FGS Global E-Mail: berlincures-eu@fgsglobal.com SOURCE: Berlin Cures Holding AG View the original press release on accesswire.com